Navigation Links
Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference
Date:9/29/2011

e impact of tinnitus on activities of daily living. Both OTO-104 doses resulted in reductions in THI Total Score from baseline as early as one month following treatment.  Furthermore, these THI Total Scores continued to decrease throughout the entire three month follow-up period, suggesting continued improvement in tinnitus symptoms experienced by patients treated with OTO-104.  By contrast, the study's placebo group demonstrated little change in THI Total Score from baseline during the three month follow-up period.  

As previously reported, results from this study showed OTO-104 to be safe and well-tolerated at both doses tested when delivered via a single IT injection.  It is important to note that despite demonstrating meaningful clinical activity in the areas of vertigo and tinnitus, this study was not powered to demonstrate statistical significance.  Based on these study results, Otonomy will initiate a Phase 2 clinical trial of OTO-104 in Meniere's disease during the fourth quarter of 2011.

"These new results provide the first demonstration of OTO-104's clinical activity in a cohort of Meniere's disease patients experiencing frequent vertigo episodes," stated Paul R. Lambert, M.D., professor and chair of the department of otolaryngology – head and neck surgery, Medical University of South Carolina, and the study's lead investigator.  "Furthermore, the continued reduction in vertigo frequency and improvement in tinnitus symptoms for the 12 mg OTO-104 group observed through three months of follow-up provides a strong rationale for initiating broader clinical evaluations of this sustained release product."

A total of 44 patients with unilateral Meniere's disease were enrolled in this prospective, randomized, double-blind, placebo-controlled multicenter study.  Patients participated in a one-month baseline period to characterize disease status, followed by randomization to receive a single IT injection
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Otonomy Introduces Scientific Advisory Board
2. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
3. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
4. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
10. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
11. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Smith & Nephew (LSE:SN, NYSE: SNN ... its entry into the forefoot market with the ... Comprised of three separate repair options, the HAT-TRICK ... and reconstruction, a metatarsal osteotomy guide, and a ... also known as hammer toe correction. ...
(Date:7/31/2014)... July 31, 2014 The global market ... million by 2020, according to a new study by ... and theranostics, and the subsequent introduction of advanced cancer ... market growth over the next six years. Moreover, the ... such as cancer, coupled with disease triggering lifestyle habits ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... JOLLA, Calif. , July 30, 2014 ... ), a biopharmaceutical company leading the discovery and development ... will report financial results and highlights for the quarter ... after the U.S. financial markets close. ... Wednesday, August 6, 2014, at 5:00 pm Eastern Daylight ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... N.Y., June 25 Lixte,Biotechnology Holdings (OTC Bulletin ... Neurological Disorders and Stroke (NINDS), National,Institutes of Health ... Research and Development Agreement (CRADA) to develop,drugs for ... in March,2006 was extended through September 2009., ...
... MichBio announced that,Johnson & Johnson Vice Chairman, Christine A. ... and Conference November 18-19 in Novi,Michigan. MichBio is the ... is the state,s premier life science event attracting,more than ... is one of the most respected professionals in the ...
... titled “Avanta AC™ Advanced Ceramics Solutions as ... white paper outlines the challenges in manufacturing ... as well as the advantages of SACHEM’s ... are critical to a variety of leading ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3Christine Poon Will Keynote MichBio Expo 2Christine Poon Will Keynote MichBio Expo 3 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
(Date:7/30/2014)... effects of climate change on the world,s animal ... factors, according to a new paper by a ... of Queensland, and other organizations. The authors claim ... the point when it comes to climate change. ... scientists focus on the "direct" threats of changing ...
(Date:7/30/2014)... The San Antonio Life Sciences Institute (SALSI), a joint ... (UTSA) and The University of Texas Health Science Center ... Postdoc Initiative Pilot Program. The winners, Emily Boice from ... will receive $25,000 for their project titled, "Novel engineered ... post-ischemic environment." , Boice and Huang,s research is focused ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... 2013 The Damon Runyon Cancer Research Foundation ... its spring 2013 Clinical Investigator Award Committee review. ... are outstanding early career physician-scientists conducting patient-oriented cancer ... of the nation,s leading scientists and clinicians. ...
... other conditions caused by malfunctions in the body,s nerve ... treat. The problem is that one medicine may help ... which drugs will work with individual patients may be ... seemingly identical neurons can behave the same even though ...
... discovered a mechanism that triggers chronic inflammation in ... today in Nature Immunology , suggest a ... the way to a new class of therapies ... diseases without crippling the immune system. Alzheimer,s, atherosclerosis ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 2Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 3Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 4Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 5Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 6Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 7Nerve cells can work in different ways with same result 2Researchers discover new way to block inflammation 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: